Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Oracle's (ORCL) stock jumped on Wednesday after fiscal third-quarter results and outlook beat estimates and drew positive ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
HCM Defender 100 Index ETF OverviewHoward Capital Management / Large Growth The fund seeks to achieve its investment objective by investing at least 80% of its net assets, including borrowings for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results